ArticleFrontiers in immunology2020
Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- Cord Blood Platelet-Poor Plasma Functionalizes Polycaprolactone Scaffolds for Coupled Vascularization and Osteogenesis in Bone Tissue Engineering.Tissue engineering and regenerative medicine · 2026Article
- Cord Blood-Derived Versus Homologous Donor Platelet-Rich Plasma (PRP) in Early Knee Osteoarthritis: A Single-Center, Randomized, Double-Blind Pilot Clinical Trial.Bioengineering (Basel, Switzerland) · 2026Article
- Article
- Tumor-Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation.MedComm · 2026Review
- Article
- Platelet Lysate-Based Biomaterials for Regenerative Tissue Engineering: A Comprehensive Review.International journal of nanomedicine · 2026Review
- Proteomic Insights into the Retinal Response to PRGF in a Mouse Model of Age-Related Macular Degeneration.Medicina (Kaunas, Lithuania) · 2025Article
- Platelets in Dry Eye Disease: A Narrative Review of Biological Mechanisms and Therapeutic Applications Derived from Platelets.Life (Basel, Switzerland) · 2025Review
- Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts.Blood transfusion = Trasfusione del sangue · 2025Article
- Umbilical cord blood-derived platelet-rich plasma as a coating substrate supporting cell adhesion and biological activities of wound healing.European journal of medical research · 2025Article
- Why might cord blood be a better source of platelets for transfusion to neonates?Blood transfusion = Trasfusione del sangue · 2024Review
- Cord blood-derived biologics lead to robust axonal regeneration in benzalkonium chloride-injured mouse corneas by modulating the Il-17 pathway and neuropeptide Y.Molecular medicine (Cambridge, Mass.) · 2024Article
- Platelet-Rich Plasma (PRP) in Dermatology: Cellular and Molecular Mechanisms of Action.Biomedicines · 2023Review
- Multi-component cord blood banking: a proof-of-concept international exercise.Blood transfusion = Trasfusione del sangue · 2023Article
- Impact of umbilical cord mesenchymal stromal/stem cell secretome and cord blood serum in prostate cancer progression.Human cell · 2023Article
- Impressive Nasal Septum Regeneration after Cord Blood Platelet Gel (CBPG) in Extreme Premature Neonate with Non-Invasive Ventilation: A Case Report.Children (Basel, Switzerland) · 2022Article
- Evaluation of the Regenerative Potential of Platelet-Lysate and Platelet-Poor Plasma Derived from the Cord Blood Units in Corneal Wound Healing Applications: An In Vitro Comparative Study on Corneal Epithelial Cells.Current issues in molecular biology · 2022Article
- Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis.Journal of clinical medicine · 2022Article
- Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain.Frontiers in cell and developmental biology · 2021Article
- Efficiency assessment of cord blood banking and compatibility with delayed cord clamping.Blood transfusion = Trasfusione del sangueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cord blood platelet rich plasma (CB-PRP) derivatives have been investigated as potential therapeutic agents for the treatment of diverse conditions including ocular surface disease and skin ulcers. We have developed processes for the formulation of several CB-PRP preparations, which have different composition and attributes. Here we describe the molecular characteristics of these preparations and we make recommendations as to their most appropriate clinical application based on functional and immunomodulatory profiles. We show that incubation of adult peripheral blood mononuclear cells (PBMCs) with all three preparations dramatically reduced the production of INFγ and the expression of NKG2D and CD107a in NK, NKT, and T cells thus diminishing their activation, we propose that the likely mechanism is the high levels of soluble NKG2D ligands present in plasma. Of the three preparations we investigated, CB platelet lysate (PL) and platelet releaseate (PR) have higher concentrations of trophic and pro-angiogenic factors, CB platelet poor plasma (PPP) has the lowest concentration of all analytes measured. Based on these finding we propose that CB-PR is the most suitable raw material for skin wound patches, while CB-PL and PPP can be used to prepare eye drops for severe ocular surface pathologies and inflammatory conditions such as corneal ulcers or severe dry eye disease, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.